| Literature DB >> 22112845 |
A Bergamo1, C Gaiddon, J H M Schellens, J H Beijnen, G Sava.
Abstract
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22112845 DOI： 10.1016/j.jinorgbio.2011.09.030
Source DB: PubMed Journal: J Inorg Biochem ISSN： 0162-0134 Impact factor: 4.155